IP Library › Granted Patent US 7,700,138
Granted Patent B2
US 7,700,138 · App. 12/259,988 · Granted Apr 20, 2010

Jucara and Açai fruit-based dietary supplements

Assignee: K2A LLC
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,700,138
App. No.
12/259,988
Granted
Apr 20, 2010
Kind
B2
Abstract

The present disclosure relates to stable, palatable, freeze-dried, fruit-based dietary supplements. In one embodiment, the disclosures relates to compositions of Açai fruit and Jucara fruit with high antioxidant capability and cyclooxygenase-inhibitory activity, and their uses. The disclosure further provides for methods of making stable, palatable, freeze-dried, fruit-based dietary supplements from Açai fruit and Jucara fruit.

Claims (15)

1. A method of inhibiting cyclooxygenase enzyme activity in a mammal, the method comprising administering to the mammal an effective amount of a dietary supplement comprising a freeze-dried Jucara fruit pulp composition, wherein the composition comprises:

(a) a total anthocyanin concentration greater than about 1 milligram per gram total weight;

(b) an ORAC FL value greater than about 350 micromole TE per gram total weight; and

(c) a residual water content less than about 3 weight percent of the total weight, wherein the composition quenches free radicals and reduces the damage induced by pathological free radicals; or

an effective amount of a freeze-dried Jucara fruit pulp composition, wherein the composition comprises a cyclooxygenase inhibition value greater than about 15 Aspirin® mg equivalent per gram total weight; and a residual water content less than about 3 weight percent of the total weight.

2. The method of claim 1 , wherein the composition further comprises a pharmaceutically acceptable carrier.

3. The method of claim 1 , wherein the composition is administered by a route of administration selected from the group consisting of: oral, intravenous, intraperitoneal, subcutaneous, intramuscular, intraarticular, intraarterial, intracerebral, intracerebellar, intrabronchial, intrathecal, topical, and aerosol route.

4. A method of treating a disease or an injury associated with increased cyclooxygenase enzyme activity in a mammal, the method comprising administering to the mammal an effective amount of a dietary supplement comprising a freeze-dried Jucara fruit pulp composition, wherein the composition comprises:

(a) a total anthocyanin concentration greater than about 1 milligram per gram total weight;

(b) an ORAC FL value greater than about 350 micromole TE per gram total weight; and

(c) a residual water content less than about 3 weight percent of the total weight, wherein the composition quenches free radicals and reduces the damage induced by pathological free radicals; or

an effective amount of a freeze-dried Jucara fruit pulp composition, wherein the composition comprises a cyclooxygenase inhibition value greater than about 15 Aspirin® mg equivalent per gram total weight; and a residual water content less than about 3 weight percent of the total weight.

5. The method of claim 4 , wherein the composition further comprises a pharmaceutically acceptable carrier.

6. The method of claim 4 , wherein the composition is administered by a route of administration selected from the group consisting of: oral, intravenous, intraperitoneal, subcutaneous, intramuscular, intraarticular, intraarterial, intracerebral, intracerebellar, intrabronchial, intrathecal, topical, and aerosol route.

7. The method of claim 4 , wherein the disease or injury is selected from the group consisting of: cancer, colon cancer, breast cancer, inflammatory bowel disease, Crohn's disease, vascular disease, arthritis, ulcer, acute respiratory distress syndrome, ischemia-reperfusion injury, neurodegenerative disorders, autism, Parkinson's Disease, Alzheimer's Disease, gastrointestinal disease, tissue injury induced by inflammation, and tissue injury induced by an environmental toxin.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 23, 2014
From: MURDOCK, KENNETH A.; SCHAUSS, ALEXANDER G.
To: K2A INCORPORATED
Reel/Frame 033014/0752 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 23, 2014
From: K2A, INC.
To: K2A LLC
Reel/Frame 033014/0994 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 21, 2014
From: MURDOCK, KENNETH A.; SCHAUSS, ALEXANDER G.
To: K2A LLC
Reel/Frame 032981/0724 →
Continuity (3)
Division 1055050200
Provisional Application 6045688200 · Mar 21, 2003
Related Publication 20090156513A1 · Jun 18, 2009